Home / Market News / $DXCM
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

UBS Adjusts DexCom Price Target to $107 From $102, Maintains Buy Rating

Oct 30, 2026, 6:08 PM UTC · Primary ticker $DXCM

UBS has increased its price target for DexCom to $107 from $102 while maintaining a Buy rating, following the company's Q3 2026 earnings report. This adjustment reflects an updated valuation of DexCom's continuous glucose monitoring business and recent financial performance, suggesting a positive outlook from the analyst.

UBS updated its outlook on DexCom after the company's Q3 2026 earnings report, raising its price target to $107 from $102 and reaffirming a Buy rating. This indicates a positive sentiment from the analyst, likely driven by strong financial performance and the growth prospects of DexCom's continuous glucose monitoring business. For traders, this could signal continued upward momentum for DXCM stock in the short term, as analyst upgrades often provide a boost. The long-term implication is a reinforced belief in the company's valuation and market position. A key opportunity for traders is to consider the potential for further price appreciation following this positive analyst coverage.

$DXCM positive Price target increase and maintained Buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.